Summit Therapeutics (SUMM)

 

SUMM Share PerformanceMore

52 week high262.00 04/10/16
52 week low82.75 04/03/16
52 week change 17.00 (11.68%)
4 week volume751,134 14/11/16

Media for (SUMM)

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Summit Enrolls Patients in the US into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid

Summit Enrolls Patients in the US into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid Summit Therapeutics plc ("Summit" or "the Company") SUMMIT ENROLS PATIENTS IN THE UNITED STATES INTO PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID IN PATIENTS WITH DMD Oxford, UK, 16 November 2016 - Summit Therapeu...

Summit Therapeutics plc : Exercise of Options

Summit Therapeutics plc: Exercise of Options Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 24 October 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announc...

Summit Therapeutics plc : Holding(s) in Company

Summit Therapeutics plc: Holding(s) in Company TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Summit Therapeutics PLC Sedol BN40HZ0 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting r...

Summit Therapeutics plc : Exercise of Options

Summit Therapeutics plc: Exercise of Options Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 14 October 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announc...

Summit Therapeutics plc : Exercise of Options

Summit Therapeutics plc: Exercise of Options Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 11 October 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announce...

Summit Therapeutics plc : Exercise of Options

Summit Therapeutics plc: Exercise of Options Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 7 October 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announce...

Summit Presents Preclinical DMD Data at 21st Congress of World Muscle Society

Summit Presents Preclinical DMD Data at 21st Congress of World Muscle Society Summit Therapeutics plc ("Summit" or "the Company") SUMMIT THERAPEUTICS PRESENTS PRECLINICAL DMD DATA AT THE 21 ST INTERNATIONAL CONGRESS OF THE WORLD MUSCLE SOCIETY Summit reports on development of new, automated biomarker tool...

FTSE closes close to its record high

The FTSE 100 continued to rally closer to its record high from last April. The blue chip index rose 2% to 7,120 as the pound...

Fundamental DataMore

EPS-41
Dividend yield0 %

Latest discussion posts More

  • Re: Rabbit out of hat?

    I have just researched my posts for SUMM and found the following. 10-07-14 Hold Consolidation The MP Word - Consolidation = Synonym = amalgamate, ...
    4-Oct-2016
    The MP
  • Re: Rabbit out of hat?

    Forgot the strong buy!
    4-Oct-2016
    alltold9
  • Re: Rabbit out of hat?

    Great call 'bobson' #4 next stop also good call. Happy days ahead.
    4-Oct-2016
    alltold9

Users' HoldingsMore

Users who hold Summit Therapeutics also hold..
LLOYDS GRP.20%
RANGE RES.18%
ROYAL BANK SCOT15%
ROCKHOPPER13%
TESCO13%

Codes & Symbols

ISINGB00BN40HZ01
SymbolsSUMM, LSE:SUMM, SUMM.L, SUMM:LN, LON:SUMM, XLON:SUMM